Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar

BACKGROUND: Peroxisome proliferator-activated receptor (PPAR) agonists may have favorable outcomes on non-alcoholic fatty liver disease. This study serves as proof of concept to evaluate whether dual PPAR-α/γ agonists improve non-invasive tests of liver steatosis and fibrosis. METHODS: This is a pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Grobbee, Esmée J., de Jong, Vivian D., Schrieks, Ilse C., Tushuizen, Maarten E., Holleboom, Adriaan G., Tardif, Jean-Claude, Lincoff, A. Michael, Schwartz, Gregory G., Castro Cabezas, Manuel, Grobbee, Diederick E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665379/
https://www.ncbi.nlm.nih.gov/pubmed/36378671
http://dx.doi.org/10.1371/journal.pone.0277706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665379/
https://www.ncbi.nlm.nih.gov/pubmed/36378671
http://dx.doi.org/10.1371/journal.pone.0277706

Ejemplares similares